Catalog No.
FHC09621
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Conjugation
FITC
Applications
FCM
Target
p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
P04626
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
MAB 2C4
Note
For research use only.
ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27., PMID:40281007
Carboplatin Co-loaded 5-Fluorouracil Nanoparticles Conjugated with Trastuzumab for Targeted Therapy in HER2+ Heterogeneity Breast Cancer., PMID:40281210
HER2-Low Breast Cancer-Current Knowledge and Future Directions., PMID:40282933
Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study., PMID:40283010
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial., PMID:40293644
Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer., PMID:40295068
Enhanced cytotoxicity of T-DM1 in HER2-low carcinomas via autophagy inhibition., PMID:40315224
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial., PMID:40318646
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers., PMID:40319675
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study., PMID:40339592
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer., PMID:40340861
Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis., PMID:40341092
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial., PMID:40341383
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy., PMID:40341444
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC., PMID:40349139
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial., PMID:40350430
Positron Emission Tomography and Optical Imaging to Monitor Bioorthogonal Diels-Alder Click Chemistry of Trastuzumab with a Porphyrin., PMID:40353799
Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial., PMID:40354993
Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option☆., PMID:40359710
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)., PMID:40360544
HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab., PMID:40365451
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial., PMID:40367619
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence., PMID:40374812
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer., PMID:40374836
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality., PMID:40377029
Molecular and clinicopathological characteristics of invasive breast cancers with HER2-ultralow expression., PMID:40379141
Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience., PMID:40380283
Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients., PMID:40391840
Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping., PMID:40399910
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy., PMID:40404737
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study., PMID:40405072
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells., PMID:40418656
Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease., PMID:40421956
Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models., PMID:40426308
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine., PMID:40428777
Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma., PMID:40433373
Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer., PMID:40437017
Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients., PMID:40437155
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial., PMID:40441802
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency., PMID:40445758
Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations., PMID:40448190
T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer., PMID:40455140
Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376
Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors., PMID:40469307
Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040
Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer., PMID:40489875
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type., PMID:40512776
For research use only. Not for human or drug use.
